ATE484521T1 - Zyklische agonisten des crf - Google Patents

Zyklische agonisten des crf

Info

Publication number: ATE484521T1
Authority: AT; Austria
Prior art keywords: phe12; glu30; cyclo; nle21; lys33
Prior art date: 1997-05-30

Application number

AT98923787T

Other languages

English (en)

Inventor

Jean Rivier

Original Assignee

Salk Inst For Biological Studi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-30

Filing date

1998-05-27

Publication date

2010-10-15

1998-05-27 Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE484521T1 publication Critical patent/ATE484521T1/de

Links

239000000556 agonist Substances 0.000 title abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 abstract 1
UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 abstract 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
235000008206 alpha-amino acids Nutrition 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
LJGOZJHDEQHJRI-SITYYSIOSA-N α-helical crf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(C)C)C1=CNC=N1 LJGOZJHDEQHJRI-SITYYSIOSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5751—Corticotropin releasing factor [CRF] (Urotensin)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Endocrinology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Neurosurgery (AREA)

AT98923787T 1997-05-30 1998-05-27 Zyklische agonisten des crf ATE484521T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/865,772 US5824771A (en)	1994-12-12	1997-05-30	Cyclic CRF agonists
PCT/US1998/010720 WO1998054222A1 (en)	1997-05-30	1998-05-27	Cyclic crf agonists

Publications (1)

Publication Number	Publication Date
ATE484521T1 true ATE484521T1 (de)	2010-10-15

Family

ID=25346194

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98923787T ATE484521T1 (de)	1997-05-30	1998-05-27	Zyklische agonisten des crf

Country Status (7)

Country	Link
US (1)	US5824771A (de)
EP (1)	EP0988320B1 (de)
JP (1)	JP4166289B2 (de)
AT (1)	ATE484521T1 (de)
AU (1)	AU7599798A (de)
DE (1)	DE69841938D1 (de)
WO (1)	WO1998054222A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326463B1 (en) *	1994-12-12	2001-12-04	The Salk Institute For Biological Studies	Cyclic CRF agonists
AU2001289916A1 (en) *	2000-09-22	2002-04-02	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6670140B2 (en) *	2001-03-06	2003-12-30	The Procter & Gamble Company	Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
WO2003011823A2 (en) *	2001-08-01	2003-02-13	The Salk Institute For Biological Studies	Crfr1 selective ligands
US7192923B2 (en) *	2002-01-16	2007-03-20	The Procter & Gamble Company	Corticotropin releasing factor 2 receptor agonists
US6849600B2 (en) *	2002-03-25	2005-02-01	The Regents Of The University Of California, Berkeley	Corticotropin-releasing hormone analogs
US20090035298A1 (en) *	2007-04-23	2009-02-05	Washington University In St. Louis	Methods to treat alzheimer's disease or other amyloid beta accumulation associated disorders
CA2822442C (en)	2010-12-22	2021-03-16	The Salk Institute For Biological Studies	Cyclic crf antagonist peptides
EP3379222B1 (de)	2017-03-22	2020-12-30	Methode Electronics Malta Ltd.	Auf magnetoelastik basierte sensoranordnung
US10670479B2 (en)	2018-02-27	2020-06-02	Methode Electronics, Inc.	Towing systems and methods using magnetic field sensing
US11221262B2 (en)	2018-02-27	2022-01-11	Methode Electronics, Inc.	Towing systems and methods using magnetic field sensing
US11084342B2 (en)	2018-02-27	2021-08-10	Methode Electronics, Inc.	Towing systems and methods using magnetic field sensing
US11491832B2 (en)	2018-02-27	2022-11-08	Methode Electronics, Inc.	Towing systems and methods using magnetic field sensing
US11014417B2 (en)	2018-02-27	2021-05-25	Methode Electronics, Inc.	Towing systems and methods using magnetic field sensing
US11135882B2 (en)	2018-02-27	2021-10-05	Methode Electronics, Inc.	Towing systems and methods using magnetic field sensing
GB201816621D0 (en)	2018-10-12	2018-11-28	Univ Leuven Kath	Prevention or treatment of adrenal insuffiency in critically ill patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4632789A (en) *	1985-01-31	1986-12-30	Reid Philip L	Gas humidification apparatus
US5109111A (en) *	1988-09-23	1992-04-28	The Salk Institute For Biological Studies	CRF antagonists
US5278146A (en) *	1988-09-30	1994-01-11	The Salk Institute For Biological Studies	CRF analogs
CA1340964C (en) *	1988-09-30	2000-04-18	Jean E. F. Rivier	Crf analogs
US5064939A (en) *	1990-02-06	1991-11-12	The Salk Institute For Biological Studies	Cyclic gnrh antagonists
US5235036A (en) *	1991-05-31	1993-08-10	The Salk Institute For Biological Studies	Crf analogs
US5245009A (en) *	1990-03-23	1993-09-14	The Salk Institute For Biological Studies	CRF antagonists
US5493006A (en) *	1993-06-16	1996-02-20	The Salk Institute For Biological Studies	Cyclic CRF analogs
US5663292A (en) *	1994-12-12	1997-09-02	The Salk Institute For Biological Studies	Cyclic CRF analogs

1997
- 1997-05-30 US US08/865,772 patent/US5824771A/en not_active Expired - Lifetime
1998
- 1998-05-27 AT AT98923787T patent/ATE484521T1/de not_active IP Right Cessation
- 1998-05-27 AU AU75997/98A patent/AU7599798A/en not_active Abandoned
- 1998-05-27 DE DE69841938T patent/DE69841938D1/de not_active Expired - Lifetime
- 1998-05-27 JP JP55078698A patent/JP4166289B2/ja not_active Expired - Fee Related
- 1998-05-27 EP EP98923787A patent/EP0988320B1/de not_active Expired - Lifetime
- 1998-05-27 WO PCT/US1998/010720 patent/WO1998054222A1/en not_active Ceased

Also Published As

Publication number	Publication date
JP4166289B2 (ja)	2008-10-15
DE69841938D1 (de)	2010-11-25
AU7599798A (en)	1998-12-30
WO1998054222A1 (en)	1998-12-03
JP2002511067A (ja)	2002-04-09
EP0988320A1 (de)	2000-03-29
EP0988320B1 (de)	2010-10-13
US5824771A (en)	1998-10-20

Legal Events

Date	Code	Title	Description
2011-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69841938D1 (de)	2010-11-25	Zyklische agonisten des crf
WO1996019499A3 (en)	1996-09-19	Improved cyclic crf antagonists
Odermatt et al.	1983	Structural diversity and domain composition of a unique collagenous fragment (intima collagen) obtained from human placenta
Papkoff	1974	Chemical and biological properties of the subunits of pregnant mare serum gonadotropin
KR920016463A (ko)	1992-09-24	펩티드의 제조방법
Bailey et al.	1979	Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules
IE59488B1 (en)	1994-03-09	Eukaryotic fusion proteins, the preparation and use there of, and means for carrying out the process
NO965411L (no)	1997-02-14	N-terminalt forlengede proteiner uttrykt i gjær
NO963225L (no)	1996-09-25	Multivariant IL-3 hematopoiese-fusjonsprotein
DK0479912T3 (da)	1994-10-10	Fremgangsmåde til hæmning af N-endereglens forløb i levende celler
DE3875538D1 (de)	1992-12-03	Aminoluciferine, verfahren zu deren herstellung und ihre verwendung.
DE3486154D1 (de)	1993-07-01	Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung.
YU50502A (sh)	2005-09-19	Postupak za prečišćavanje farmakološki aktivnih proteina pomoću katjonske izmenjivačke hromatografije
ES2095255T3 (es)	1997-02-16	Analogos de sustitucion de peptidos magainina.
ES8700272A1 (es)	1986-10-16	Procedimiento para la preparacion y purificacion de peptidos
Knight et al.	1984	A collagenous glycoprotein found in dissociative extracts of foetal bovine nuchal ligament. Evidence for a relationship with type VI collagen
FI930626A0 (fi)	1993-02-12	Proteinstruktur hos vaexttoxingelonin
Abedin et al.	1981	Type V collagen: the presence of appreciable amounts of α3 (V) chain in uterus
Kemme et al.	1986	The major protein of bull seminal plasma is a secretory product of seminal vesicle
PE47599A1 (es)	1999-05-14	Proteinas antiobesidad
Sasaki et al.	1983	Chemical studies on the isolated collagen-like and globular fragments of complement component C1q comparative studies on bovine and human C1q
Hackeng et al.	1998	Chemical synthesis of human protein S thrombin‐sensitive module and first epidermal growth factor module
DK1448772T3 (da)	2007-11-19	Fremgangsmåder til forögelse af ekspressionsniveauer af human TNF-receptor
PL316069A1 (en)	1997-03-17	Novel derivatives of biotin and method of obtaining them as well as pharmaceutic preparation and method of preparing same
Hochuli et al.	1987	Specificity of the immunoadsorbent used for large-scale recovery of interferon α-2a